The use of CpG DNA as a mucosal vaccine adjuvant.
CpG DNA has been shown to be a potent adjuvant in many disease models. Most studies using CpG DNA as adjuvant have used parenteral delivery, but more effective protection against mucosal pathogens could be achieved with effective mucosal immunization. Recently, mucosal immunization with CpG DNA as an adjuvant has been shown to induce both systemic (humoral and cellular) and mucosal antigen-specific immune responses. This review will concentrate on the use of CpG DNA as an adjuvant for the induction of mucosal immunity.
McCluskie
M J
MJ
Coley Pharmaceutical Canada, Ottawa, Ontario. mmccluskie@LRI.ca
Weeratna
R D
RD
Payette
P J
PJ
Davis
H L
HL
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D001249:Asthma / Q000517:prevention & control; D006801:Humans; D018928:Immunity, Mucosal; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage / Q000494:pharmacology*; D014612:Vaccines / Q000008:administration & dosage*
D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; D009838:Oligodeoxyribonucleotides; D014612:Vaccines